Results for tumour size translation from English to Slovenian

tumour size
0,39-0,9

tumour
tumor

tumour pain
bolečina zaradi raka

tumour promotor
promotor tumorja

tumour haemorrhage*
krvavitev iz tumorja

ewing's tumour
ewingova družina tumorjev

effect on tumour growth and/or size
učinek na rast tumorja in/ali njegovo velikost:

treatment by pegvisomant does not reduce tumour size.
zdravljenje s pegvisomantom ne zmanjša velikosti tumorjev.

increase in pain, tumour size, redness around the tumour
zvečanje bolečine, velikosti tumorja, rdečine okrog tumorja;

note: tumour size is based on sum of longest dimensions of target lesions.
opomba: velikost tumorja temelji na seštevku najdaljših dimenzij ciljnih lezij.

around a quarter of the patients in this study also had a reduction in tumour size.
pri približno četrtini bolnikov v tej študiji je bilo opaženo tudi zmanjšanje velikosti tumorja.

the evidence available so far showed promising results in terms of tagrisso’s ability to reduce tumour size.
do zdaj razpoložljivi dokazi kažejo obetavne rezultate v smislu zmožnosti zdravila tagrisso za zmanjševanje velikosti tumorja.

all patients with these tumours should be carefully monitored in order to avoid any eventual progression in tumour size under treatment.
vse bolnike s takšnimi tumorji je treba skrbno spremljati, da bi se izognili morebitnemu večanju tumorja med zdravljenjem.

other efficacy outcomes included objective response, disease control, change in tumour size and health-related quality of life.
preostali opazovani dogodki za ocenjevanje učinkovitosti so bili: objektivni odziv, nadzor bolezni, sprememba velikosti tumorja in zdravstvena kakovost življenja.

4 density/size: modified inverse choi criteria to evaluate tumour size and density using hounsfield units based on ct/mri
4 gostota/velikost: prilagojena inverzna choieva merila za oceno velikosti in gostote tumorja z uporabo hounsfieldovih enot na podlagi ct/mri

a population pk analysis suggested no difference in cl of nivolumab based on age, gender, race, tumour type, tumour size, and hepatic impairment.
analiza podatkov populacijske farmakokinetike ne kaže razlik v očistku nivolumaba glede na starost, spol, raso, vrsto tumorja, velikost tumorja in okvaro jeter.

people with metastatic breast cancer who received abraxane where another therapy had failed, were more likely to experience a reduction in tumour size, and lived longer than people who took an alternative therapy.
pri ljudeh z metastatskim rakom dojk, ki so po neuspehu drugačne oblike zdravljenja prejemali zdravilo abraxane, je pogosteje prišlo do zmanjšanja velikosti tumorja, živeli pa so dlje kot bolniki, ki so uporabljali alternativno obliko zdravljenja.

in addition to dependence on body size, time-dependent clearance was higher in subjects with higher baseline tumour size, which is consistent with target-mediated elimination.
poleg odvisnosti od telesne velikosti je bil od-časa-odvisen-očistek večji pri bolnikih z večjim tumorjem v izhodišču, kar je skladno s tarčno posredovanim izločanjem (target-mediated elemination).

this regimen was administered every three weeks for 4 cycles in case at least a minor response (≥ 25 % reduction in bidimensionally measured tumour size) was observed after 2 cycles.
to terapevtsko shemo so uporabljali vsake tri tedne za 4 cikle, če so po 2 ciklih opazili vsaj manjši odziv (> 25 % zmanjšanje dvodimenzionalno merjene velikosti tumorja).

sylvant was more effective than placebo in reducing tumour size and disease symptoms: 17 out of 53 patients who received sylvant showed a partial response and one showed a complete response, compared with none of the 26 patients who received placebo.
zdravilo sylvant je bilo učinkovitejše od placeba pri zmanjšanju velikosti tumorjev in simptomov bolezni: pri 17 od 53 bolnikov, ki so prejemali zdravilo sylvant, so opazili delni odziv, in pri enem popolni odziv, medtem ko se v skupini s placebom ni odzval nobeden od 26 bolnikov.